Drug Profile
Eftansomatropin - Genexine/Handok
Alternative Names: Eftansomatropin alfa; GX-H9; hGH-hyFc; HL 2356; HyTropin; Recombinant somatropin fusion protein; TJ 101Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Genexine
- Developer Genexine; Handok Inc
- Class Growth hormones; Hormonal replacements; Recombinant fusion proteins
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Somatotropin deficiency
Most Recent Events
- 31 Aug 2023 I-Mab Biopharma announces intention to file BLA for Somatotropin deficiency (In children) in China in 2024
- 17 Aug 2023 Efficacy and adverse events data from a phase III trial in Somatotropin deficiency released by I-Mab Biopharma
- 31 Mar 2023 Jumpcan and I-Mab Biopharma announces intention to launch of eftansomatropin in China